関連する実験動画

Updated: Sep 9, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

[アレルギー性鼻炎患者316人の急性免疫療法の安全性と関連するリスク要因の分析]

M Y Wei¹, X H Zhu¹, Y T Xiao¹

¹Department of Otorhinolaryngology Head and Neck Surgery, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

|September 1, 2025

まとめ

アレルギー性鼻炎 (AR) に対する急性免疫療法 (RIT) は,注射毎に全身性有害事象 (SAE) の発生率1. 31%を示した. 体重指数 (BMI) はこれらのSAEの重要な危険因子として特定されました.

科学分野:

アレルギーと免疫学
臨床研究
免疫療法

背景:

アレルギー性鼻炎 (AR) は,人口のかなりの部分に影響します.
ラッシュ免疫療法 (RIT) は,ARに対する従来の免疫療法より速い代替治療法です.
RITの安全性プロフィールの評価は,特に用量エスカレーションの際に,臨床実務において極めて重要です.

研究の目的:

AR患者におけるRITの安全性を評価する.
RIT中に発生する全身有害事象 (SAE) に関する危険因子を特定する.

主な方法:

家粉虫アレルギーの患者316人を再検査した後の分析.
投与量エスカレーション段階におけるSAEの発生,頻度,および重度の分析
SAEと人口統計学,血清学,肺機能のパラメータとの関連を調査する.

主要な成果:

SAEは患者の14. 24% (注射当たり1. 31%の発生率),主にグレードIで発生しました.
SAEと年齢,BMI,皮膚刺検査の強度,エオシノフィルの数/パーセント,FEV1,PEFとの間に有意な関連性が見つかりました.
多変数ロジスティック回帰では,BMIがSAEの独立リスク因子として特定されました.

結論:

RITは,AR患者における用量エスカレート時に好ましい安全性プロファイルを示しています.
ほとんどのSAEは軽度で管理可能なリスクを示しています
身体質量指数 (BMI) の上昇は,RIT中の全身的有害作用の重要なリスク因子です.

さらに関連する動画

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

関連する概念動画

Allergic Reactions

Allergic Reactions

Asthma-I: Introduction

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...

Hypersensitivities

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...